Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapies. With Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade as cornerstones, emerging therapies such as Bluebird Bio / Celgene’s bb2121 and GlaxoSmithKline's GSK2857916 are pursuing initial approvals for the treatment of multiple myeloma and can expect premium pricing. Further, as a result of expected label expansions of current therapies, multiple myeloma regimens will increasingly include high-priced therapies. Understanding the market access drivers that are important to payers and oncologists will be essential in maximizing these therapies’ uptake.
- What roles do key brands such as Darzalex and Empliciti play in the treatment of multiple myeloma in the United States, and in what treatment settings are they typically prescribed?
- How broadly do MCOs cover multiple myeloma agents on their formularies, particularly for the regimens that include both oral and IV agents? What kind of restrictions do they apply to control usage?
- Do payers believe that the efficacy of the various therapies justifies their cost, and which drug do they think performs the best on clinical and other attributes?
- What are physicians’ views on emerging therapies such as bb2121 and GSK2857916, as well as the subcutaneous formulation of Darzalex? How do clinicians expect their prescribing to change, and what factors, if any, will drive these changes?
Survey of 100 hematologist-oncologists in the United States Survey of 32 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)
KEY DRUGS COVERED
Current therapies: Darzalex, Empliciti, Kyprolis, Ninlaro, Pomalyst, Revlimid, Velcade
Emerging therapies: bb2121, GSK2857916, subcutaneous Darzalex
- Reimbursement and contracting
- Access and prescribing
- Special topics
- Opportunities and challenges for emerging therapies.
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.
- Detailed, Expanded Analysis (US)
- Access & Reimbursement Multiple Myeloma US November 2019
Author(s): Paul Wilcock. PhD; Chris Lewis; Snigdha Gupta, Ph.D
Since October 2015, Dr. Wilcock has been a Business Insights Analyst in the oncology team at Decision Resources Group. He has experience in various indications including metastatic malignant melanoma and renal cell carcinoma, and will have a major focus on gastric cancer going forward. Previously, Dr. Wilcock was a Research Funding Manager at Cancer Research UK, where he developed a deep understanding of drug discovery, predominantly in the academic setting. He gained his doctorate from the University of Manchester where he utilized Systems Biology to explore the role of cell signaling and hypoxia in oral cancer.
Chris Lewis serves as primary research manager, Access and Reimbursement, with responsibility for coordination, content review and content generation of the market access and reimbursement insights at DRG. Content is based on online surveys of managed care organizations and physicians and expert analysis of reimbursement and prescribing patterns of key therapies treating various disease states. Lewis was an analyst/senior analyst for the group’s HealthLeaders-InterStudy subsidiary for eight years, specializing in the managed care and pharmacy benefit management industries. Throughout her tenure, she has produced the Health Plan Analysis reports for California, New York, New Jersey, Connecticut, and Pennsylvania and authored DRG’s series of pharmacy benefit manager profiles. She has also conducted numerous webinars for the group. She is a seasoned journalist with a in communications from California State University, Sacramento.
Dr. Snigdha Gupta is a Lead Analyst in the oncology team at Decision Resources Group with expertise in multiple oncology indications including non-small cell lung cancer and multiple myeloma. Prior to joining DRG, Dr. Snigdha Gupta was a subject matter expert in immune-oncology, autoimmunity and dealt in generating in-depth framework based scientific analyses for client projects. In her previous organizations, she was involved in the planning and execution of the IND enabling preclinical studies. She has been instrumental in the stage-up of two small molecules at Bioxcel Therapeutics and Daiichi Sankyo Pharma India Pvt. Ltd. Dr. Gupta holds in infectious diseases from the Indian Institute of Chemical Biology, Jadavpur University, Kolkata while her post-doctoral fellowship is from the Mucosal immunology labs of National Institute of Immunology, New Delhi.